{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:16:40Z","timestamp":1788293800915,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euros.2026.07.004","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:14:02Z","timestamp":1784834042000},"page":"12-22","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intravaginal Delivery of Oxybutynin: An Alternative Administration Route to Improve its Pharmacokinetic and Pharmacodynamic Effects"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0514-9220","authenticated-orcid":false,"given":"Sophie I.","family":"Peltenburg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk C.","family":"Meijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Somohardjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk W.","family":"Elzevier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke I.M.","family":"van Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marije E.","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Juachon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Strugala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa J.","family":"Tibboel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koos","family":"Burggraaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart W.J.","family":"Hellebrekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi B.","family":"Klarenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2026.07.004_b0005","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","article-title":"Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: A systematic review and network meta-analysis","volume":"8","author":"Mostafaei","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euros.2026.07.004_b0010","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s00192-012-1915-8","article-title":"Oxybutynin: past, present, and future","volume":"24","author":"Jirschele","year":"2013","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.euros.2026.07.004_b0015","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/BF00558247","article-title":"The pharmacokinetics of oxybutynin in man","volume":"35","author":"Douchamps","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.euros.2026.07.004_b0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/1756287215626312","article-title":"An update on the use of transdermal oxybutynin in the management of overactive bladder disorder","volume":"8","author":"Cohn","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euros.2026.07.004_b0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003495-200969030-00008","article-title":"Transdermal oxybutynin","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.euros.2026.07.004_b0030","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1701-2163(16)35440-8","article-title":"Treatments for overactive bladder: focus on pharmacotherapy","volume":"34","author":"Geoffrion","year":"2012","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.euros.2026.07.004_b0035","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/AOG.0b013e31818e8aa4","article-title":"Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms","volume":"112","author":"Gopal","year":"2008","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.euros.2026.07.004_b0040","unstructured":"European Medicines Agency. Kentera: EPAR \u2013 product information; 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kentera."},{"key":"10.1016\/j.euros.2026.07.004_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114293","article-title":"Advances and future perspectives in epithelial drug delivery","volume":"186","author":"Mohammed","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.euros.2026.07.004_b0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/gels8020099","article-title":"Application of sol-gels for treatment of gynaecological conditions-physiological perspectives and emerging concepts in intravaginal drug delivery","volume":"8","author":"Thapa","year":"2022","journal-title":"Gels"},{"key":"10.1016\/j.euros.2026.07.004_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jps.21793","article-title":"Non-invasive systemic drug delivery: developability considerations for alternate routes of administration","volume":"99","author":"Mathias","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.euros.2026.07.004_b0060","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003552.pub2","article-title":"Skin patch and vaginal ring versus combined oral contraceptives for contraception","volume":"1","author":"Lopez","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euros.2026.07.004_b0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jconrel.2008.08.012","article-title":"The origins and evolution of \u2018controlled\u2019 drug delivery systems","volume":"132","author":"Hoffman","year":"2008","journal-title":"J Control Release"},{"key":"10.1016\/j.euros.2026.07.004_b0070","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.euros.2026.07.004_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1872211313666190215141507","article-title":"Nanocarriers for vaginal drug delivery","volume":"13","author":"Iqbal","year":"2019","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"10.1016\/j.euros.2026.07.004_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fertnstert.2004.01.025","article-title":"Why consider vaginal drug administration?","volume":"82","author":"Alexander","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.euros.2026.07.004_b0085","doi-asserted-by":"crossref","DOI":"10.1080\/10717544.2023.2180113","article-title":"First-in-human study to assess the pharmacokinetics, tolerability, and safety of single-dose oxybutynin hydrochloride administered via a microprocessor-controlled intravaginal ring","volume":"30","author":"de Laat","year":"2023","journal-title":"Drug Deliv"},{"key":"10.1016\/j.euros.2026.07.004_b0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/187221111795471418","article-title":"Exploring novel approaches to vaginal drug delivery","volume":"5","author":"Gupta","year":"2011","journal-title":"Recent Pat Drug Deliv Formul"},{"key":"10.1016\/j.euros.2026.07.004_b0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2004.11.034","article-title":"The vagina as a route for systemic drug delivery","volume":"103","author":"Hussain","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.euros.2026.07.004_b0100","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0168-3659(03)00277-3","article-title":"Design of a silicone reservoir intravaginal ring for the delivery of oxybutynin","volume":"91","author":"Woolfson","year":"2003","journal-title":"J Control Release"},{"key":"10.1016\/j.euros.2026.07.004_b0105","series-title":"Nonsurgical treatments for urinary incontinence in women: A systematic review update","author":"Balk","year":"2018"},{"key":"10.1016\/j.euros.2026.07.004_b0110","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4065\/78.6.696","article-title":"Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects","volume":"78","author":"Appell","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.euros.2026.07.004_b0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.urology.2023.11.033","article-title":"Oxybutynin-associated cognitive impairment: evidence and implications for overactive bladder treatment","volume":"186","author":"Chancellor","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.euros.2026.07.004_b0120","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41585-021-00504-x","article-title":"The cognitive effect of anticholinergics for patients with overactive bladder","volume":"18","author":"Welk","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euros.2026.07.004_b0125","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/SPV.0000000000001272","article-title":"Overactive bladder and cognitive impairment: the American Urogynecologic Society and pelvic floor disorders research foundation state-of-the-science conference summary report","volume":"29","author":"Dengler","year":"2023","journal-title":"Urogynecology (Phila)"},{"key":"10.1016\/j.euros.2026.07.004_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.euros.2026.07.004_b0135","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2006.03.057","article-title":"Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects","volume":"50","author":"Kay","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.004_b0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2013.01.002","article-title":"Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study","volume":"64","author":"Wagg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2026.07.004_b0145","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/00912700122010528","article-title":"Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system","volume":"41","author":"Todorova","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.euros.2026.07.004_b0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00191165","article-title":"Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers","volume":"47","author":"Pietzko","year":"1994","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.euros.2026.07.004_b0155","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1365-2125.2011.03936.x","article-title":"Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects","volume":"71","author":"Liem-Moolenaar","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.euros.2026.07.004_b0160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1022259011052","article-title":"Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system","volume":"20","author":"Zobrist","year":"2003","journal-title":"Pharm Res"},{"key":"10.1016\/j.euros.2026.07.004_b0165","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s11255-019-02209-y","article-title":"Efficacy and safety of anticholinergics for children or adolescents with idiopathic overactive bladder: systematic review and meta-analysis","volume":"51","author":"Noh","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.euros.2026.07.004_b0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/01674828709023862","article-title":"The gynaecological examination\u2014women\u2019s experiences and preferences and the role of the gynaecologist","volume":"6","author":"Areskog-Wijma","year":"1987","journal-title":"J Psychosom Obstet Gynecol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006555?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168326006555?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:42:58Z","timestamp":1788291778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168326006555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S2666168326006555"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2026.07.004","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravaginal Delivery of Oxybutynin: An Alternative Administration Route to Improve its Pharmacokinetic and Pharmacodynamic Effects","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2026.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}